Wang Tao, Ma Sicong, Qi Xingxing, Tang Xiaoyin, Cui Dan, Wang Zhi, Chi Jiachang, Li Ping, Zhai Bo
Department of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, P.R. China.
Mol Med Rep. 2017 Mar;15(3):1172-1178. doi: 10.3892/mmr.2017.6154. Epub 2017 Jan 26.
Human hepatocellular carcinoma (HCC) has been reported to be highly insensitive to conventional chemotherapy. In the current study, the Agilent Whole Human Genome Oligo Microarray (4x44 K) was used in order to identify the differentially expressed genes between HCC and adjacent tissues, and the top 22 differentially expressed genes were confirmed through reverse transcription‑quantitative polymerase chain reaction. Among the identified differences in gene expression, expression of tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) was markedly higher in HCC tissue than in adjacent tissue. Previous studies have suggested that TNFRSF12A may serve a role in tumor growth and metastasis, thus in the current study, TNFRSF12A was knocked down in the SMMC7721 cell line through siRNA. This demonstrated that cells exhibited reduced reproductive and metastatic capacity ex vivo. Thus, the results of the current study suggest that TNFRSF12A may be a candidate therapeutic target for cancer including HCC, and additional genes that exhibited significantly different expression from normal adjacent tissues require further study.
据报道，人类肝细胞癌（HCC）对传统化疗高度不敏感。在本研究中，使用安捷伦全人类基因组寡核苷酸微阵列（4x44 K）来鉴定HCC与相邻组织之间差异表达的基因，并通过逆转录-定量聚合酶链反应确认了前22个差异表达基因。在鉴定出的基因表达差异中，肿瘤坏死因子受体超家族成员12A（TNFRSF12A）在HCC组织中的表达明显高于相邻组织。先前的研究表明，TNFRSF12A可能在肿瘤生长和转移中起作用，因此在本研究中，通过小干扰RNA（siRNA）在SMMC7721细胞系中敲低TNFRSF12A。这表明细胞在体外的增殖和转移能力降低。因此，本研究结果表明，TNFRSF12A可能是包括HCC在内的癌症的候选治疗靶点，并且与正常相邻组织表现出显著不同表达的其他基因需要进一步研究。
